- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04532307
Isisekelo Sempilo Trial to Optimize Peer (Thetha Nami) Delivery of HIV Prevention to Young People in Rural KwaZulu-Natal
Isisekelo Sempilo: HIV Prevention Embedded in Sexual Health: A Pilot Trial to Optimize Peer (Thetha Nami) Delivery of HIV Prevention and Care to Adolescents and Young Adults in Rural KwaZulu-Natal.
Study Overview
Status
Conditions
Detailed Description
Study design: We will conduct a 2x2 factorial design intervention pilot trial including 1500 men and women aged 16-29-years old and living in the AHRI surveillance area. The study duration will be 18 months. We will randomly offer one of four combinations of interventions in a factorial trial to 1500 consenting men and women aged 16-29-years old and living in our study area.
Study outcomes: (1) a reduction of the proportion of individuals with infectious HIV (i.e. remaining HIV negative or with an undetectable HIV viral load on treatment if positive) and (2) uptake of comprehensive HIV prevention services, including Pre-Exposure Prophylaxis (PrEP) if negative and antiretroviral (ART) if positive. We will also evaluate uptake of contraception, incidence of pregnancy, mental health and quality of life.
Study Population and Recruitment: Research assistants (RAs) will approach 3000 randomly selected 16-29-year old males and females selected from our demographic surveillance area in their homes. From our experience we expect that 2000 will still be eligible, i.e. aged 16-29 and still living in the surveillance area. RAs will provide information about the study to all eligible participants and consent (in the case of 16-17-year-olds assent with parental consent) them to a) be offered an intervention and b) to be followed up at 12 months to measure the outcome. We anticipate that n=1500 [75% (73-77%)] will consent to participate.
Interventions: a) Standard of Care (SOC): RAs refer participants to adolescent and youth friendly services with family planning, HIV testing and ART if positive and PrEP for those eligible and negative (according to the South African national Department of Health guidelines); b) SRH enhanced arm (Isisekelo Sempilo): Self-collected vaginal and urine samples are collected at enrolment. RAs provide clinic appointment for results, treatment and sexual health promotion and services. These promote fertility and family planning; HIV testing, and benefits of ART including Undetectable=Uninfectious amongst positives and PrEP for those eligible and negative; c) Peer-support (Thetha-Nami): RAs refer the participant to a peer navigator in their community. Peer navigators will assess their health, social and educational needs, provide mentorship, and help them access the services they need. The peer navigator will facilitate attendance, adherence and retention at the clinic; or d) SRH + peer-support.
Data Collection: We will measure linkage to clinical services within 60 days of randomisation and adverse events. At 12 months from enrolment RAs will approach all those who consented at baseline to conduct a tablet-based survey on uptake of HIV prevention and care services, uptake of contraception and pregnancy, mental health (using PHQ9), and quality of life. They will collect dry blood spot for HIV ELISA and HIV viral load, and offer point of-care HIV testing, STI testing and treatment. We will conduct a process evaluation to assess service users and providers and the community experience and any social harms. We will establish the cost of delivering the intervention in each arm.
Analysis: With n=1500 we have the power to show an increase in linkage to clinical services from 10% in SOC to 22% with peer-support or SRH only and 38% with peer-support and SRH. We also have the power to detect a reduction in the proportion of 16-29-year olds with a detectable HIV viral load from 7% to 3.5% at 12 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
KwaZulu-Natal
-
uMkanyakude, KwaZulu-Natal, South Africa
- AHRI
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
-
Exclusion Criteria:
- Under 16 years and above 30 years of age, unable to consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Standard of Care SOC
Youth friendly services at Isisekelo Sempilo clinics
|
Research assistants refer the consenting participants to Isisekelo Sempilo adolescent and youth friendly services with HIV testing, treatment if positive and PrEP eligibility screening and offer if negative and family planning
|
|
Experimental: SRH enhanced Isisekelo Sempilo
Self-collected vaginal and urine samples for gonorrhea, chlamydia and trichomonas
|
Research assistants refer the consenting participants to Isisekelo Sempilo adolescent and youth friendly services with HIV testing, treatment if positive and PrEP eligibility screening and offer if negative and family planning
Self-collected vaginal and urine samples are collected at enrolment.
Research assistants then provide an Isisekelo Sempilo clinic referral appointment for results, treatment, HIV testing, sexual health, fertility, and family planning counselling, including the personal benefits of ART and Undetectable=Uninfectious among those infected, and PrEP for those eligible and who are negative.
|
|
Experimental: Peer-support (Thetha-Nami)
Peer support and needs assessment from an area-based peer navigator
|
Research assistants refer the consenting participants to Isisekelo Sempilo adolescent and youth friendly services with HIV testing, treatment if positive and PrEP eligibility screening and offer if negative and family planning
The research assistants refer the participant to a Thetha Nami peer-navigator in their community.
Peer navigators will assess their health, social and educational needs, provide mentorship, and help them access the services they need.
The peer navigator will facilitate attendance, adherence and retention at the Isisekelo Sempilo clinic.
|
|
Experimental: SOC + SRH + peer-support
Combination of all arms
|
Research assistants refer the consenting participants to Isisekelo Sempilo adolescent and youth friendly services with HIV testing, treatment if positive and PrEP eligibility screening and offer if negative and family planning
Self-collected vaginal and urine samples are collected at enrolment.
Research assistants then provide an Isisekelo Sempilo clinic referral appointment for results, treatment, HIV testing, sexual health, fertility, and family planning counselling, including the personal benefits of ART and Undetectable=Uninfectious among those infected, and PrEP for those eligible and who are negative.
The research assistants refer the participant to a Thetha Nami peer-navigator in their community.
Peer navigators will assess their health, social and educational needs, provide mentorship, and help them access the services they need.
The peer navigator will facilitate attendance, adherence and retention at the Isisekelo Sempilo clinic.
A combination of interventions 2 and 3, to include both self-collected STI testing, nurse led testing and counseling, and referral to a Thetha Nami peer navigator to encourage clinic attendance and sexual health promotion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of adolescent and youth who have transmissible HIV
Time Frame: 12 months from date of recruitment
|
Measured as the proportion of participants who consent to participate with a detectable HIV viral load (>400 copies per ml) 12 months after enrolment per arm
|
12 months from date of recruitment
|
|
Proportion of adolescents and youth who uptake HIV prevention and treatment services
Time Frame: 60 days
|
Measured as the proportion of participants who consent who link to clinical services for HIV testing and PrEP/ART counselling within 60 days per arm
|
60 days
|
|
Proportion of adolescents and youth who agree to participate in the trial
Time Frame: 12 months
|
Measured as proportion of those who are eligible consenting to offer of interventions who accept interventions and 12 month follow-up
|
12 months
|
|
Proportion of adolescents and youth from whom the outcome measure of HIV viral load can be ascertained at 12 months follow-up.
Time Frame: 12 months after enrollment
|
Measured as the proportion of all those enrolled that provide dry blood spots for the measurement of HIV (i.e.
proportion with an HIV viral load >400 copies per ml) in >75% of those who enrolled at baseline irrespective of engagement in any intervention
|
12 months after enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of adolescent and youth who are HIV positive that start antiretroviral treatment
Time Frame: 12 months
|
Measured as the proportion who are HIV positive who start treatment per arm; time from randomization to HIV test and treatment initiation per arm.
|
12 months
|
|
Proportion of adolescent and youth who are HIV negative who start PrEP and remain negative
Time Frame: 12 months
|
Measured as the proportion of those who are PrEP eligible (based on the South African PrEP eligibility criteria) who initiate PrEP when tested negative; Proportion who remain on PrEP at the end of follow-up; and proportion of new HIV diagnosis per arm
|
12 months
|
|
Proportion of adolescent and youth that have poor sexual health outcome
Time Frame: 12 months
|
Measured as the proportion of enrolled who have a new pregnancy and/or Sexually Transmitted Infection per arm
|
12 months
|
|
Proportion of adolescents and youth that have a poor mental health outcome
Time Frame: 12 months from enrolment
|
Measured as the proportion screening positive for mental health outcome per arm
|
12 months from enrolment
|
|
Proportion of adolescents and youth that are retained in HIV prevention or care
Time Frame: 12 months from enrolment
|
Measured as the Proportion attending at least 3 out of 4 followup visits (month 1, 3, 6, 9) and receiving appropriate HIV test per arm
|
12 months from enrolment
|
|
Proportion of adolescents and youth that have transmissible HIV (on treatment analysis)
Time Frame: 12 months from enrolment
|
Measured as the proportion of participants who uptake clinical services who have detectable HIV viral load (>400 copies per ml) 12 months after enrolment per arm
|
12 months from enrolment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Process evaluation
Time Frame: 18 months
|
Process evaluation of the intervention fidelity; description of acceptability of the intervention components (what works for whom and in which context); unexpected adverse events to the individual and community; and what were the sociodemographic patterns of uptake, retention and adherence?
|
18 months
|
|
Costings
Time Frame: 18 months
|
What is the cost of the comprehensive SRH component?
What is the cost of the peer navigator component?
What is the incremental cost per additional person starting and retained in UTT and PrEP at 6 months in each of the arms compared to SoC.
|
18 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Maryam Shahmanesh, PhD, University College London (UCL) and Africa Health Research Institute (AHRI)
Publications and helpful links
General Publications
- Chidumwa G, Chimbindi N, Herbst C, Okeselo N, Dreyer J, Zuma T, Smith T, Molina JM, Khoza T, McGrath N, Seeley J, Pillay D, Tanser F, Harling G, Sherr L, Copas A, Baisley K, Shahmanesh M. Isisekelo Sempilo study protocol for the effectiveness of HIV prevention embedded in sexual health with or without peer navigator support (Thetha Nami) to reduce prevalence of transmissible HIV amongst adolescents and young adults in rural KwaZulu-Natal: a 2 x 2 factorial randomised controlled trial. BMC Public Health. 2022 Mar 7;22(1):454. doi: 10.1186/s12889-022-12796-8.
- Shahmanesh M, Okesola N, Chimbindi N, Zuma T, Mdluli S, Mthiyane N, Adeagbo O, Dreyer J, Herbst C, McGrath N, Harling G, Sherr L, Seeley J. Thetha Nami: participatory development of a peer-navigator intervention to deliver biosocial HIV prevention for adolescents and youth in rural South Africa. BMC Public Health. 2021 Jul 13;21(1):1393. doi: 10.1186/s12889-021-11399-z.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Urogenital Diseases
- Genital Diseases
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- A00004-TBC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Prevention
-
Duke UniversityGilead SciencesRecruitingHIV Prevention | HIV Pre-exposure Prophylaxis | HIV Prevention Program | HIV Prevention and Care | HIV Pre-exposure Prophylaxis UseUnited States
-
University of California, Los AngelesRecruitingHIV PreventionUnited States
-
University of Alabama at BirminghamNational Institute of Mental Health (NIMH)RecruitingPrEP | HIV | HIV Prevention | PrEP UptakeUnited States
-
Institute of HIV Research and Innovation Foundation...National Institutes of Health (NIH)RecruitingHIV Prevention | PrEP Adherence | HIV Related StigmaThailand
-
Medstar Health Research InstituteNational Institute of Mental Health (NIMH)CompletedHIV Prevention ProgramUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)RecruitingHIV Prevention | Healthy VolunteerUnited States
-
Prof Mags BeksinskaCompletedHIV Prevention | Pregnancy PreventionSouth Africa
-
Yale UniversityCompletedHIV Prevention | STI PreventionUnited States
-
Centers for Disease Control and PreventionUniversity of Minnesota; The Fenway Institute; AIDS Action Committee of Massachusetts and other collaboratorsCompletedHIV Prevention | STD PreventionUnited States
-
University of MichiganNational Institute of Mental Health (NIMH)Enrolling by invitationHIV Prevention | Pre-Exposure Prophylaxis (PrEP)United States
Clinical Trials on Standard of Care SOC
-
Rhizen Pharmaceuticals SAIncozen Therapeutics Pvt LtdCompleted
-
TakedaCompletedGaucher DiseaseUnited States
-
SeaStar MedicalWithdrawnCOVID-19 | Continuous Renal Replacement Therapy | Pulmonary Edema
-
HeNan Sincere Biotech Co., LtdUnknown
-
Michelle LopezCompleted
-
Axolotl BiologixSerenaGroup, Inc.RecruitingDiabetic Foot | Foot Ulcer | Diabetic Foot Ulcer | Ulcer FootUnited States
-
Merakris TherapeuticsNot yet recruitingDiabetic Foot Ulcer
-
George Washington UniversityMedtronicCompleted
-
AtriCure, Inc.Completed
-
Summa Therapeutics, LLCNot yet recruitingPeripheral Arterial Disease Below the Knee | Peripheral Arterial Disease, Rutherford 4 and 5 with Possibility to Improve VascularizationUnited States